Ascentage Pharma Group International vs HUTCHMED (China)
AAPG and HCM side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AAPG and HCM compare
HUTCHMED (China) grew revenue faster over the last twelve months (−13.0% versus −41.5% for Ascentage Pharma Group International).
HUTCHMED (China) keeps more of each dollar of sales as profit, with a net margin of 83.3% compared with −216% at Ascentage Pharma Group International.
HUTCHMED (China) scores higher on the StockData Score (5 against 3 for Ascentage Pharma Group International), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AAPG | HCM |
|---|---|---|
| Size and price | ||
| Share price | $14.62 | $14.90 |
| Change, 1 year | −55.6% | −2.5% |
| Change, 5 years | – | −51.5% |
| Beta (5Y) | 0.79 | 0.97 |
| Employees | 767 | 109 |
| StockData Score | ||
| Total score | 3 | 5 (better) |
| Valuation score | 0 | 0 |
| Growth score | 1 (better) | 0 |
| Performance score | 1 | 3 (better) |
| Health score | 1 | 2 (better) |
| Dividend score | 0 | 0 |
| Growth | ||
| Revenue growth (TTM) | −41.5% | −13.0% (better) |
| Revenue growth, 5Y average | – | 19.2% |
| Net income growth (TTM) | – | 1111% |
| EPS growth (TTM) | – | 1200% |
| Profitability | ||
| Gross margin | 91.5% (better) | 38.7% |
| Operating margin | – | −7.1% |
| Net margin | −216% | 83.3% (better) |
| FCF margin | −209% | −14.4% (better) |
| Return on equity | −156% | 36.7% (better) |
| Financial health | ||
| Debt / equity | 1.50 | 0.09 (better) |
| Interest coverage | – | −13.7× |
| Current ratio | 1.79 | 5.64 (better) |
| Piotroski F-score | – | 4 |
| Ownership | ||
| Held by institutions | 0.00% | 0.51% |
| Held by insiders | 13.0% | 0.44% |
Go deeper
- AAPG stock overview
- AAPG income statement
- AAPG valuation and score
- HCM stock overview
- HCM income statement
- HCM valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.